July 17, 2024 11:20 AM EDT
News Briefing

SK to pay up to $571M in new ra­dio­phar­ma deal; Aslan lets go of all em­ploy­ees

ENDPOINTS

Plus, news about Aclaris, OMERS Life Sci­ences, Draup­nir Bio, Pharnext and Ac­tu­ate:

SK Bio­phar­ma­ceu­ti­cals li­cens­es Full-Life’s ra­dio­phar­ma drug: The deal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times